<DOC>
	<DOCNO>NCT01874678</DOCNO>
	<brief_summary>Objectives : 1 . Primary Objective : To bridge data efficacy term overall response rate TS-1 plus cisplatin Taiwanese advance NSCLC patient gain Japanese population 2 . Secondary Objectives : A . To assess progression free survival B . To assess overall survival C. To bridge safety profile assess toxicity tolerability</brief_summary>
	<brief_title>A Study TS-1 Plus Cisplatin Patients With Advanced Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>To eligible inclusion , subject must fulfill follow criterion : 1. histologically cytologically confirm nonsmall cell bronchogenic carcinoma 2 . Stage IIIb IV disease 3. presence least one measurable disease define lesion measure least 1 dimension ≥20 mm conventional CT/MRI ≥10 mm spiral CT scan 4. performance status ECOG 0 , 1 5. age 20 74 year registration 6. life expectancy least 12 week 7. ability take oral study medication ( TS1 ) 8. voluntarily sign write informed consent form . malignancy exception curative treat nonmelanoma skin cancer cervical carcinoma situ within 5 year prior entry study previously receive chemotherapy therapy systemic antitumor effect significant comorbid medical condition , include , limited , heart failure , renal failure , hepatic failure , hemorrhagic peptic ulcer , mechanical paralytic ileus , poorly control diabetes fertile woman childbearing potential unless use reliable appropriate contraceptive method throughout treatment period three month follow cessation treatment Presence mental disease psychotic manifestation Participation another clinical trial investigational drug within 30 day prior entry judge ineligible physician participation study due safety concern .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>